John Freund - Profile and Investment Details

Investor Profile

John Freund is a Venture Capital, Private Equity Firm based in Palo Alto, California, United States with a diverse investment portfolio that includes companies such as Tetraphase Pharmaceuticals, Chancellor Capital Management (acquired by Invesco), Avidia, Renovis, Eledon Pharmaceuticals, Sutro Biopharma, NovaCardia, Calibra Medical, Sunesis Pharmaceuticals, Concert Pharmaceuticals, Sirtris Pharmaceuticals, Tolerx, Dicerna Pharmaceuticals, Alteer, SI-BONE, ARCA biopharma, Proteon Therapeutics, KAI Pharmaceuticals, Roche NimbleGen, Satiety, Xenoport, Collegium Pharmaceutical, Crescendo Bioscience, Intuitive Surgical, Genocea Biosciences, Sequel Pharmaceuticals, MAKO Surgical, iScribeReceptor Biologix, Targanta Therapeutics, NovaSys, Guava Technologies, Calypso Medical, iBalance Medical, Applied Genetics Technologies Corporation, NOVASYS MEDICAL, Medivance, InteKrin, SpinalMotion, MAP Pharmaceuticals, . Over time, John Freund has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether John Freund is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Hospitals, Genetics, Life Science, Information Technology (IT), Biotechnology, Genomics, Health Diagnostics, Medical, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with John Freund, as their portfolio suggests a familiarity and interest in this area.

Understanding John Freund’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.